About CEL-SCI Corporation

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also developing (and investigating) an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

When used in this report, the words "intends," "believes," "anticipated", “plans” and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2011. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
 
CEL-SCI CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 2012 and 2011
(UNAUDITED)
   
  2012     2011  
 
GRANT INCOME AND OTHER $ 106,543 $ 43,815
 
OPERATING EXPENSES:

Research and development (excluding R&D depreciation of $108,531 and $119,633 respectively, included below)
2,594,235 3,042,097
Depreciation and amortization 143,428 145,141
General & administrative   1,631,237     1,953,573  
 
Total operating expenses   4,368,900     5,140,811  
 
OPERATING LOSS (4,262,357 ) (5,096,996 )
 
OTHER EXPENSES - (12,000,000 )
 
(LOSS) GAIN ON DERIVATIVE INSTRUMENTS (4,204,327 ) 3,062,087
 
INTEREST INCOME 28,673 46,707
 
INTEREST EXPENSE   (55,948 )   (41,402 )
 
NET LOSS (8,493,959 ) (14,029,604 )
 
MODIFICATIONS OF WARRANTS - (1,068,369 )
INDUCEMENT OF WARRANTS   (1,593,000 )   -  
 
NET LOSS AVAILABLE TO COMMON SHAREHOLDERS $ (10,086,959 ) $ (15,097,973 )
 
NET LOSS PER COMMON SHARE $ (0.04 ) $ (0.07 )
BASIC
$ (0.04 ) $ (0.09 )
DILUTED
 

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
BASIC 247,369,587 207,089,841
 
DILUTED 247,369,587 207,089,841
 
 
CEL-SCI CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
SIX MONTHS ENDED MARCH 31, 2012 and 2011
(UNAUDITED)
   
  2012     2011  
 
GRANT INCOME AND OTHER $ 111,567 $ 706,633
 
OPERATING EXPENSES:

Research and development (excluding R&D depreciation of $225,282 and $235,824 respectively, included below)
5,050,420 6,306,525
Depreciation and amortization 281,853 286,288
General & administrative   3,484,927     3,526,850  
 
Total operating expenses   8,817,200     10,119,663  
 
OPERATING LOSS (8,705,633 ) (9,413,030 )
 
OTHER EXPENSES - (12,000,000 )
 
(LOSS) GAIN ON DERIVATIVE INSTRUMENTS (3,247,857 ) 1,115,692
 
INTEREST INCOME 57,728 99,586
 
INTEREST EXPENSE   (179,410 )   (82,804 )
 
NET LOSS (12,075,172 ) (20,280,556 )
 
ISSUANCE OF ADDITIONAL SHARES (250,000 ) -
MODIFICATIONS OF WARRANTS (325,620 ) (1,068,369 )
INDUCEMENT OF WARRANTS   (1,593,000 )   -  
 
NET LOSS AVAILABLE TO COMMON SHAREHOLDERS $ (14,243,792 ) $ (21,348,925 )
 
NET LOSS PER COMMON SHARE
BASIC $ (0.06 ) $ (0.10 )
 
DILUTED $ (0.06 ) $ (0.10 )
 

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
BASIC 237,912,177 206,090,265
 
DILUTED 237,912,177 206,090,265
 

If you liked this article you might like

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

A Neurotrope Stock Promotion Scheme Is Underway, but Who's Paying for It?

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

4 Stocks Under $10 Making Big Moves Higher

Cel-Sci's Enrollment Math Doesn't Add up